New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
09:43 EDTNEPT, ACST, ENZYNeptune, Acasti say patent settlement with Enzymotec not finalized
Neptune Technologies (NEPT) and Acasti Pharma (ACST), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec (ENZY) that would resolve the International Trade Commission investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. the Administrative Law Judge presiding over the pending ITC Investigation previously stay the proceedings through February 5 to give the parties more time to finalize a settlement agreement. To date, the parties have reached an impasse on certain fundamental settlement terms, including terms to which Enzymotec had already agreed in the parties' signed term sheet. Consequently, as strongly encouraged by the ITC, Neptune will participate in the ITC's Mediation Program in a final attempt to reach a mutually satisfactory agreement. The mediation process is expected to be completed over the next 45 to 60 days.
News For NEPT;ACST;ENZY From The Last 14 Days
Check below for free stories on NEPT;ACST;ENZY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
10:11 EDTNEPTNeptune Technologies receives USPTO patent
Reference Link
July 15, 2014
17:56 EDTNEPTNeptune Technologies reports Q1 revenue C$3.64M vs. C$6.08M last year
Gross profit as a percent of revenue was 14% for the current quarter, versus 10% for the corresponding prior year quarter. Reports Q1 Adjusted EBITDA (C$3.77M) vs. (C$2.7M) in the prior year. Reports Q1 net loss (C$5.7M) vs. (C$3.38M) last year.
July 9, 2014
11:24 EDTNEPTHigh option volume stocks
High option volume stocks: GIMO NEPT BPOP AVAV CBSO LL BOBE KWK GNC TCS
08:08 EDTACSTAcasti Pharma completes Phase II TRIFECTA, Pharmacokinetic trials
Acasti Pharma announces the completion of two trials, the Phase II double-blind, placebo-controlled, or TRIFECTA, study and the Pharmacokinetic trial. The primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia. Given that the stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study. The corporation intends to unblind the study and top-line results are expected by the end of September, with full data coming out in the following quarter. Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre. Top-line results are expected to be available by the end of September, with full data coming out in the following quarter.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use